[go: up one dir, main page]

RU2017101323A3 - - Google Patents

Download PDF

Info

Publication number
RU2017101323A3
RU2017101323A3 RU2017101323A RU2017101323A RU2017101323A3 RU 2017101323 A3 RU2017101323 A3 RU 2017101323A3 RU 2017101323 A RU2017101323 A RU 2017101323A RU 2017101323 A RU2017101323 A RU 2017101323A RU 2017101323 A3 RU2017101323 A3 RU 2017101323A3
Authority
RU
Russia
Application number
RU2017101323A
Other versions
RU2017101323A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017101323A publication Critical patent/RU2017101323A/ru
Publication of RU2017101323A3 publication Critical patent/RU2017101323A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2017101323A 2014-06-17 2015-06-11 Конденсированные бициклические гетероароматические производные в качестве ингибиторов киназы RU2017101323A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410817.9A GB201410817D0 (en) 2014-06-17 2014-06-17 Therapeutic agents
GB1410817.9 2014-06-17
PCT/EP2015/063052 WO2015193169A1 (en) 2014-06-17 2015-06-11 Fused bicyclic heteroaromatic derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
RU2017101323A RU2017101323A (ru) 2018-07-25
RU2017101323A3 true RU2017101323A3 (ru) 2018-12-24

Family

ID=51266753

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017101323A RU2017101323A (ru) 2014-06-17 2015-06-11 Конденсированные бициклические гетероароматические производные в качестве ингибиторов киназы

Country Status (9)

Country Link
US (1) US10000497B2 (ru)
EP (1) EP3157924A1 (ru)
JP (1) JP2017518385A (ru)
CN (1) CN106559992A (ru)
BR (1) BR112016029632A2 (ru)
CA (1) CA2951349A1 (ru)
GB (1) GB201410817D0 (ru)
RU (1) RU2017101323A (ru)
WO (1) WO2015193169A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
BR112020014431A2 (pt) 2018-01-17 2020-12-01 Glaxosmithkline Intellectual Property Development Limited inibidores de pl4kiiibeta
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
US20220062243A1 (en) * 2019-01-11 2022-03-03 Jeffrey S. Glenn P14-Kinase Inhibitors with Anti-Cancer Activity
MX2021011501A (es) 2019-03-21 2022-01-18 Univ Leland Stanford Junior Inhibidores de pi4-cinasa y métodos para usar los mismos.
CN112574214B (zh) * 2019-07-30 2021-09-28 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (ru) * 1973-05-22 1974-11-26
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
WO2005002514A2 (en) * 2003-06-13 2005-01-13 Echelon Biosciences Incorporated Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof
WO2005110413A2 (en) 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
CA2754890C (en) 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
DK2585467T3 (en) * 2010-06-24 2016-06-13 Gilead Sciences Inc PYRAZOLO [1,5-A] PYRIMIDINES AND TRIAZINES AS ANTIVIRAL AGENTS
HUE034347T2 (en) * 2010-09-29 2018-02-28 Intervet Int Bv N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
GB201115665D0 (en) * 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
BR112016029632A2 (pt) 2017-08-22
US10000497B2 (en) 2018-06-19
GB201410817D0 (en) 2014-07-30
US20170121337A1 (en) 2017-05-04
WO2015193169A1 (en) 2015-12-23
JP2017518385A (ja) 2017-07-06
CA2951349A1 (en) 2015-12-23
CN106559992A (zh) 2017-04-05
RU2017101323A (ru) 2018-07-25
EP3157924A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
BR112016017520A2 (ru)
BR112016016951A2 (ru)
BR112016016756A2 (ru)
BR112016016478A2 (ru)
BR112016016978A2 (ru)
BR112016018948A2 (ru)
BR112016018327A2 (ru)
BR112016015605A2 (ru)
BR112016018868A2 (ru)
BR112016018384A2 (ru)
BR112016018278A2 (ru)
BR112016018582A2 (ru)
BR112016018556A2 (ru)
BR112016015385A2 (ru)
BR112016017262A2 (ru)
BR112016008129A2 (ru)
BR112016016933A2 (ru)
BR112016016364A2 (ru)
BR112016014460A2 (ru)
BR112016017713A2 (ru)
BR112016016298A2 (ru)
BR112016018944A2 (ru)
BR112016015645A2 (ru)
BR112016000228A2 (ru)
BR112016016149A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190624